147 Results

People

  1. Horwitz
    Horwitz
  2. Salles
    Salles
  3. Usmani
    Usmani
  4. Zelenetz
    Zelenetz
  5. Kumar
    Kumar
  6. Perales
    Perales
  7. Batlevi
    Batlevi
  8. Moskowitz
    Moskowitz
  9. Palomba
    Palomba
  10. Shah
    Shah

Groups

  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)
  7. Weinberg Fellows (25)
  8. Biostatistics Service (23)
  9. Population Sciences Research Program (21)
  10. Survivorship Research (21)
  1. "overall response rate"
Formats
  1. Journal Article (114)
  2. Editorial (10)
  3. Review (8)
  4. Correspondence (6)
  5. Research Letter (6)
  6. Meeting Abstract (2)
  7. Guidelines (1)
Groups
  1. Department of Medicine (118)
  2. Hematologic Malignancies, Division of (74)
  3. Solid Tumor Oncology Division (61)
  4. Center for Hematologic Malignancies (53)
  5. Epidemiology and Biostatistics (26)
  6. Lymphoma (25)

More Groups

People
  1. Andrew Zelenetz (9)
  2. Gilles Salles (9)
  3. Saad Usmani (9)
  4. Steven Horwitz (9)
  5. Anita Kumar (8)
  6. Miguel-Angel Perales (8)

More People

Years
  1. 2025 (23)
  2. 2024 (41)
  3. 2023 (32)
  4. 2022 (27)
  5. 2021 (17)
  6. 2020 (6)

More Years

Publications
  1. Leukemia and Lymphoma (13)
  2. Blood (10)
  3. Haematologica (9)
  4. ESMO Open (7)
  5. Leukemia (7)
  6. Annals of Oncology (6)

More Publications

Publishers
  1. Elsevier Inc. (25)
  2. Nature Publishing Group (19)
  3. American Society of Hematology (16)
  4. Taylor & Francis Group (13)
  5. Oxford University Press (11)
  6. Ferrata Storti Foundation (9)

More Publishers

Results (147)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Comparative effectiveness of ZUMA-5 (axi-cel) vs SCHOLAR-5 external control in relapsed/refractory follicular lymphoma
    Journal Article

    Ghione, P.; Palomba, M. L.; Patel, A. R.; Bobillo, S.; Deighton, K.; Jacobson, C. A.; Nahas, M.; Hatswell, A. J.; Jung, A. S.; Kanters, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Radiation therapy for relapsed or refractory diffuse large B-cell lymphoma: What is the right regimen for palliation?
    Journal Article

    Wright, C. M.; Dreyfuss, A. D.; Baron, J. A.; Maxwell, R.; Mendes, A.; Barsky, A. R.; Doucette, A.; Svoboda, J.; Chong, E. A.; Jones, J. A.; more...
    Advances in Radiation Oncology (2022)

    Fulltext@MSK | Save
  • Rituximab, methotrexate, carmustine, etoposide, and prednisone (RMBVP) for the treatment of relapsed/refractory primary central nervous system lymphoma: A retrospective single-center study
    Journal Article

    Reiss, S. N.; Yerram, P.; Modelevsky, L.; Grommes, C.
    Leukemia and Lymphoma (2022)

    Fulltext@MSK | Save
  • Clinically significant risk thresholds in the management of primary cutaneous melanoma: A survey of melanoma experts
    Journal Article

    Bartlett, E. K.; Grossman, D.; Swetter, S. M.; Leachman, S. A.; Curiel-Lewandrowski, C.; Dusza, S. W.; Gershenwald, J. E.; Kirkwood, J. M.; Tin, A. L.; Vickers, A. J.; more...
    Annals of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Update on the systematic review/meta-analysis of uncomplicated bone metastases treated with external beam radiation
    Editorial

    Behroozian, T.; Navarro, I.; Hoskin, P.; Johnstone, C.; Recht, A.; Menten, J.; Oldenburger, E.; van der Linden, Y.; van der Velden, J. M.; Nguyen, Q. N.; more...
    Radiotherapy and Oncology (2022)

    Fulltext@MSK | Save
  • Practice patterns in the management of thyroid cancer
    Editorial

    Shaha, A. R.; Pantvaidya, G.; Tuttle, R. M.
    Journal of Surgical Oncology (2022)

    Fulltext@MSK | Save
  • Efficacy and safety of ripretinib in patients with KIT-altered metastatic melanoma
    Journal Article

    Janku, F.; Bauer, S.; Shoumariyeh, K.; Jones, R. L.; Spreafico, A.; Jennings, J.; Psoinos, C.; Meade, J.; Ruiz-Soto, R.; Chi, P.
    ESMO Open (2022)

    Fulltext@MSK | Save
  • Impact of trough concentrations of regorafenib and its major metabolites M-2 and M-5 on overall survival of chemorefractory metastatic colorectal cancer patients: Results from a multicentre GERCOR TEXCAN phase II study
    Journal Article

    Rousseau, B.; Boukerma, A. K.; Henriques, J.; Cohen, R.; Lucidarme, O.; Borg, C.; Tournigand, C.; Kim, S.; Bachet, J. B.; Mazard, T.; more...
    European Journal of Cancer (2022)

    Fulltext@MSK | Save
  • Chemotherapy-free regimens in frontline follicular lymphoma
    Editorial

    Batlevi, C. L.
    Blood (2022)

    Fulltext@MSK | Save
  • Abemaciclib in combination with endocrine therapy for patients with hormone receptor-positive, HER2-negative metastatic breast cancer: A phase 1b study
    Journal Article

    Tolaney, S. M.; Beeram, M.; Beck, J. T.; Conlin, A.; Dees, E. C.; Puhalla, S. L.; Rexer, B. N.; Burris, H. A. 3rd; Jhaveri, K.; Helsten, T.; more...
    Frontiers in Oncology (2022)

    Fulltext@MSK | Save